/
IDYA
$36.60-$0.16 (-0.42%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$3.5B
96M shares
52-week range
$20.50 – $39.28
86% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.39%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$15.60
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $19.5M | $27.9M | $50.9M | $23.4M | $7.0M | $218.7M |
| Cost of revenue | $886.0K | $1.2M | $1.4M | $1.7M | $2.1M | $4.0M | $3.8M | $4.6M |
| Gross profit | −$886.0K | −$1.2M | $18.2M | $26.2M | $48.8M | $19.4M | $3.2M | $214.1M |
| Gross margin | — | — | 92.9% | 93.8% | 95.9% | 82.9% | 45.2% | 97.9% |
| R&D | $31.7M | $34.3M | $39.7M | $58.2M | $89.5M | $129.5M | $294.7M | $314.7M |
| Operating income | −$36.4M | −$44.3M | −$35.3M | −$50.3M | −$62.5M | −$134.4M | −$327.0M | −$159.3M |
| EBITDA | −$33.5M | −$40.7M | −$33.1M | −$48.0M | −$56.6M | −$109.0M | −$270.6M | −$109.1M |
| Net income | −$34.3M | −$42.0M | −$34.5M | −$49.8M | −$58.7M | −$113.0M | −$274.5M | −$113.7M |
| Net margin | — | — | -176.6% | -178.1% | -115.2% | -483.0% | -3921.1% | -52.0% |
| EPS (diluted) | -2.41 | -1.90 | -1.31 | -1.41 | -1.42 | -1.96 | -3.36 | -1.28 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $36M | $-4.30 | $-4.89–$-3.78 | 11 |
| 2027 | $117M | $-3.69 | $-4.83–$-1.41 | 10 |
| 2028 | $255M | $-2.95 | $-4.05–$0.19 | 11 |
| 2029 | $576M | $-0.90 | $-1.72–$0.08 | 4 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
IDEAYA Biosciences, Inc. Common Stock
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
www.ideayabio.com- Employees
- 145
- IPO / List date
- May 23, 2019
- HQ
- SOUTH SAN FRANCISCO, CA
Held by traders on TradeandTell
No one on the platform currently holds IDYA.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-03-31 | 357,600 | $5.9M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded IDYA yet.
